HUE049543T2 - Variáns flavivírusburok-szekvenciák és alkalmazásaik - Google Patents

Variáns flavivírusburok-szekvenciák és alkalmazásaik

Info

Publication number
HUE049543T2
HUE049543T2 HUE17726515A HUE17726515A HUE049543T2 HU E049543 T2 HUE049543 T2 HU E049543T2 HU E17726515 A HUE17726515 A HU E17726515A HU E17726515 A HUE17726515 A HU E17726515A HU E049543 T2 HUE049543 T2 HU E049543T2
Authority
HU
Hungary
Prior art keywords
envelope sequences
flavivirus envelope
variant
variant flavivirus
sequences
Prior art date
Application number
HUE17726515A
Other languages
English (en)
Inventor
Peter Laing
Original Assignee
Excivion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excivion Ltd filed Critical Excivion Ltd
Publication of HUE049543T2 publication Critical patent/HUE049543T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/18Togaviridae; Flaviviridae
    • C07K14/1816Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • G01N2333/183Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
HUE17726515A 2016-05-20 2017-05-22 Variáns flavivírusburok-szekvenciák és alkalmazásaik HUE049543T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1608896.5A GB2550418A (en) 2016-05-20 2016-05-20 An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Publications (1)

Publication Number Publication Date
HUE049543T2 true HUE049543T2 (hu) 2020-09-28

Family

ID=56369688

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17726515A HUE049543T2 (hu) 2016-05-20 2017-05-22 Variáns flavivírusburok-szekvenciák és alkalmazásaik

Country Status (18)

Country Link
US (2) US11028133B2 (hu)
EP (2) EP3458471B1 (hu)
JP (1) JP7121396B2 (hu)
KR (1) KR20190008896A (hu)
CN (1) CN109415414A (hu)
AU (1) AU2017268479B2 (hu)
BR (1) BR112018073681A2 (hu)
CA (1) CA3025076A1 (hu)
DK (1) DK3458471T3 (hu)
GB (2) GB2550418A (hu)
HU (1) HUE049543T2 (hu)
IL (1) IL263054A (hu)
MX (1) MX2018014198A (hu)
PE (1) PE20190130A1 (hu)
PH (1) PH12018502441A1 (hu)
RU (1) RU2018142835A (hu)
SG (1) SG11201810157QA (hu)
WO (2) WO2017201543A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
WO2018208547A1 (en) * 2017-05-10 2018-11-15 University Of Massachusetts Bivalent dengue/hepatitis b vaccines
TWI658848B (zh) * 2018-02-13 2019-05-11 國立清華大學 茲卡病毒疫苗組合物及其應用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
WO2020198865A1 (en) * 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
MX2022005498A (es) * 2019-11-07 2022-08-11 Inst Microbiology Cas Vacuna del zika/dengue y aplicación de la misma.
CA3198059A1 (en) * 2020-10-07 2022-04-14 Sanofi Pasteur Improved diagnostic tests
GB202019843D0 (en) 2020-12-16 2021-01-27 Coronex Ltd Lateral flow tests
WO2024081625A1 (en) * 2022-10-11 2024-04-18 University Of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
CA2616026A1 (en) 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
WO2013151764A1 (en) * 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Also Published As

Publication number Publication date
JP2019520058A (ja) 2019-07-18
CA3025076A1 (en) 2017-11-23
RU2018142835A (ru) 2020-06-22
MX2018014198A (es) 2019-08-21
US11028133B2 (en) 2021-06-08
GB2550418A (en) 2017-11-22
GB201719423D0 (en) 2018-01-03
WO2017201543A1 (en) 2017-11-23
KR20190008896A (ko) 2019-01-25
CN109415414A (zh) 2019-03-01
GB201608896D0 (en) 2016-07-06
WO2018215495A1 (en) 2018-11-29
BR112018073681A2 (pt) 2019-02-26
EP3458471A1 (en) 2019-03-27
PE20190130A1 (es) 2019-01-17
AU2017268479B2 (en) 2021-04-01
AU2017268479A1 (en) 2018-12-06
US20190300580A1 (en) 2019-10-03
DK3458471T3 (da) 2020-07-06
EP3630796A1 (en) 2020-04-08
IL263054A (en) 2019-01-31
US20200215180A1 (en) 2020-07-09
JP7121396B2 (ja) 2022-08-18
US11401307B2 (en) 2022-08-02
SG11201810157QA (en) 2018-12-28
PH12018502441A1 (en) 2019-05-15
EP3458471B1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
HK1254848A1 (zh) 祖先病毒序列及其應用
IL275468A (en) Incretin analogs and their use
IL263054A (en) Various flavivirus envelope sequences and their uses
IL275469A (en) Incretin analogs and their use
HK1251183A1 (zh) 生物綴合物及其用途
IL265796A (en) Preparations comprising short peptides derived from pedf and their uses
IL256137B (en) Corneal implant and its use
IL287825A (en) Structures of sirp-alpha variant and their uses
HK1249447A1 (zh) Igfbp3及其應用
HK1248729A1 (zh) 細胞毒性hexim1肽和其用途
IL248424A0 (en) Neuroprotective substances and their uses
HK1247122A1 (zh) 組合及其用途
IL254241A0 (en) Etv2 and its uses
HK1250915A1 (zh) 組合物和其用途
HK1247220A1 (zh) 環狀甘丙肽類似物及其用途
IL248863A0 (en) Preparations containing il-31 and their use
GB201911959D0 (en) Immunogenic compositions and uses therefor
PL3221860T3 (pl) Zespół podstawy i korpusu
SG11201610918RA (en) Peptides and uses thereof
IL248576A0 (en) Anti-lice preparation and its uses
GB201403765D0 (en) ORCTL3 Sequences and their uses